Resminostat
- Generic Name
- Resminostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O4S
- CAS Number
- 864814-88-0
- Unique Ingredient Identifier
- 1578EUB98L
- Background
Resminostat has been used in trials studying the treatment of Sezary Syndrome, Mycosis fungoides, Hodgkin's Lymphoma, Hepatocellular Carcinoma, and Lymphoma, T-Cell, Cutaneous, among others.
- Associated Conditions
- -
- Associated Therapies
- -
4SC AG (FRA:VSC) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
4SC AG (FRA:VSC) filed a marketing authorization application for Resminostat with the EMA, received orphan drug designation in Switzerland, and showed positive RESMAIN study results. Operating costs were reduced by 18%, but the company reported a loss of EUR4 million in H1 2024. Decided not to pursue Resminostat registration in the US due to FDA response, and faces financial challenges with high monthly cash usage.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath